The RTS,S/AS01 Malaria Vaccines has undergone several phase III clinical trials and has been shown to provide partial protection against malaria, particularly in young children. In a large clinical trial conducted in sub-Saharan Africa, the Malaria Vaccines was found to reduce the incidence of clinical malaria by about 40% in children 5-17 months of age and by about 27% in infants 6-12 weeks of age.
Another vaccine candidate, PfSPZ, developed by Sanaria Inc., uses live-attenuated sporozoites (the parasite stage transmitted by mosquitoes) to induce a protective immune response. PfSPZ has shown promise in early clinical trials, providing complete protection against malaria in a significant proportion of vaccinated individuals.
There are also several other Malaria Vaccines candidates in various stages of development, including vaccines based on recombinant proteins, virus-like particles, and DNA. These vaccines aim to provide protection against different stages of the parasite's life cycle, including the blood stage, liver stage, and transmission stage.
Read More About Malaria Vaccines Market- http://latestcmiblogs.weebly.com/article/a-malaria-vaccine-protects-against-malaria-a-mosquito-borne-infectious-disease
